DFTX
Definium TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The positive case is that DFTX has one of the cleaner late-stage psychiatric development setups in small-cap biotech: a fully enrolled first Phase 3 MDD study, a second Phase 3 MDD study moving forward, additional GAD framing around DT120, and cash, cash equivalents, and investments of about $411.6 million at December 31, 2025 that management says should fund operations into 2028 [#10-K-2026-02-26]. If April messaging de-risks the path to late-Q2 data and the Emerge readout is supportive, the shares can move materially toward the existing median target neighborhood.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.7.
What can break
Despite runway into 2028 per the 10-K, prolonged development setbacks could eventually force a lower-quality financing outcome.
Momentum
85
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $34.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $34.14
Why
Momentum85 · Δ7d +3.7
Value41 · Δ7d +0.1
Sentiment47 · Δ7d -3.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendFlat
Δ7d
+3.7
Δ21d
-0.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
47
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.7
Δ21d
-4.0
Why this grade
Composite grade B. Momentum 85.0 / Value 41.1 / Sentiment 47.2
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$2.49B
Beta
2.62
Shares Out
98.51M
P/E (TTM) · Derived
-12.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-18.90
Rev YoY
-
EPS YoY
-345.9%
Gross Margin
-
Op Margin
-
Net Debt
-$251.89M
Current Ratio
3.30
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology